Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer's disease

Journal of Neural Transmission

Volumn 110, Issue 9, 2003, Pages 1041-1050

  Brune, S ^a   Kolsch H ^a   Ptok, U ^a   Majores, M ^a   Schulz, A ^a   Schlosser, R ^b   Rao, M L ^a   Maier, W ^a   Heun, R ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; Association; Insulin; PPAR

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE; INSULIN; LIGAND; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROID HORMONE; TRANSCRIPTION FACTOR;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; EXON; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE METABOLISM; HUMAN; INTRON; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; INSULIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0042412157     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0018-6     Document Type: Article

References (34)

1. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58: 373-379
2. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptors: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 347: 1319-1327
3. Ball MJ (1977) Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 37: 111-118
4. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24: 87-97
5. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischmann S (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107: 926-940
6. Craft S, Newcomer J, Kanne S, Dagago-Jack S, Cryer P, Sheline Y, Luby J, Dagago-Jack A, Alderson A (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17: 123-130
7. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr D (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease. Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50: 164-168
8. Cullingford TE, Dolphin CT, Sato H (2002) The peroxisome proliferators-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. Neuropharmacol 42: 724-730
9. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. J Biol Chem 20: 649-688
10. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of the nuclear hormone receptors. Cell 68: 879-887
11. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA (2001) A polymorphism, L162V in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 79: 198-204
12. Flavell DM, Jamishidi Y, Hawe E, Pineda-Torra I, Taskinen M-R, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M (2002) Peroxisome proliferator-activated receptor α gene influences progression of coronary artherosclerosis and risk of coronary artery disease. Circulation 105: 1440-1445
13. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE (2000) Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type 2 diabetic subjects. Diabetologica 43: 673-680
14. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
15. Frölich L, Blum-Degen D, Hoyer S, Riederer P (1996) Regional distribution of insulin, insulin receptors and IGF-1 receptors in post-mortem brain cortex in aging and in dementia of Alzheimer type (abstract). Neurobiol Aging 17: 184
16. Fruchart J-C, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and artherosclerosis. Curr Opin Lipidol 10: 245-257
17. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert J-M, Winegar DA, Willson TM, Fruchart J-C, Berge RK, Steals B (2000) Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642
18. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Sciene 256: 184-185
19. Hixson J, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha1. J Lipid Res 31: 545-548
20. Horrobin DF (1995) Abnormal membrane concentrations of 20 and 22 carbon essential fatty acids: a common link between risk factors, and coronary and peripheral vascular disease? Prostaglandins Leukot Essent Fatty Acids 53: 385-396
21. Isseman I, Green S (1990) Activation of a member of the steroid hormone superfamily by peroxisome proliferators. Nature 347: 645-650
22. Kainu T, Wikstrom AC, Gustafsson JA, Pelto-Huikko M (1994) Localization of the peroxisome proliferator-activated receptor in the brain. Neurorep 20: 2481-2485
23. Majores M, Kölsch H, Bagli M, Ptok U, Kockler M, Becker K, Rao ML, Maier W, Heun R (2002) The insulin gene VNTR polymorphism in Alzheimer's disease. J Neural Transm 109: 1029-1034
24. Meneilly GS, Hill A (1993) Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr 41: 710-714
25. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648
26. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal D (1998) The INS 5′ variable number of tandem repeats is associated with IGF-2 expression in humans. J Biol Chem 273: 14158-14164
27. Qiu QW, Walsh DM, Zhen Y, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. Biol Chem 49: 32730-32738
28. Reaven GM (1994) Syndrome X; 6 years later. J Intern Med [Suppl] 736: 13-22
29. Roduitt R, Morin J, Massé F, Segall L, Roche E, Newgard CB, Assimacopoulos-Jeannet F, Prentki M (2000) Glucose down-regulates the expression of the peroxisome proliferators-activated receptor-α gene in the pancreatic β-cell. J Biol Chem 275: 35799-35806
30. Schonfeld G (1994) The effects of fibrates on lipoprotein and haemostatic coronary risk factors. Artherosclerosis 111: 161-174
31. Schonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferators-activated receptor alpha (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925
32. St. George-Hyslop PH (2000) Molecular genetics of Alzheimer's disease. Biol Psychiatry 47: 183-199
33. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981
34. Vohl M-C, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde C, Cellier C, Faith JM, Després, Morgan K, Hudson TJ (2000) Molecular scanning of the PPARα gene: association of the L162V mutation with hyperapolipoproteinemia. Lipid Res 41: 941-952